Summary of Study ST003144
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001955. The data can be accessed directly via it's Project DOI: 10.21228/M8172C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST003144 |
Study Title | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity |
Study Summary | To combat the global burden of malaria, development of new drugs to replace or complement current therapies are urgently required. Here we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end stage haemoglobin digestion in asexual parasites. MMV1557817 can kill sexual stage P. falciparum, is active against murine malaria and did not show any shift in activity against a panel of parasites resistant to other antimalarials. MMV1557817-resistant P. falciparum exhibited a slow growth rate that was quickly outcompeted by wild type parasites and were sensitised to the current clinical drug, artemisinin. Overall, these results confirm MMV1557817 as a lead compound for further drug development and highlight the potential of dual inhibition of M1 and M17 as an effective multi-species drug targeting strategy. |
Institute | Monash University |
Last Name | Siddiqui |
First Name | Ghizal |
Address | 381 Royal Parade, Parkville, Melbourne, Victoria, 3052, Australia |
ghizal.siddiqui@monash.edu | |
Phone | 99039282 |
Submit Date | 2024-03-25 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2024-04-18 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001955 |
Project DOI: | doi: 10.21228/M8172C |
Project Title: | On-target, dual aminopeptidase inhibition provides cross-1 species antimalarial activity |
Project Summary: | To combat the global burden of malaria, development of new drugs to replace or complement current therapies are urgently required. Here we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end stage haemoglobin digestion in asexual parasites. MMV1557817 can kill sexual stage P. falciparum, is active against murine malaria and did not show any shift in activity against a panel of parasites resistant to other antimalarials. MMV1557817-resistant P. falciparum exhibited a slow growth rate that was quickly outcompeted by wild type parasites and were sensitised to the current clinical drug, artemisinin. Overall, these results confirm MMV1557817 as a lead compound for further drug development and highlight the potential of dual inhibition of M1 and M17 as an effective multi-species drug targeting strategy. |
Institute: | Monash University |
Last Name: | Siddiqui |
First Name: | Ghizal |
Address: | 381 Royal Parade, Parkville, Melbourne, Victoria, 3052, Australia |
Email: | ghizal.siddiqui@monash.edu |
Phone: | 99039282 |